ASCO Cancer Drug Valuation Tool Will Incorporate Patient Preferences
This article was originally published in The Pink Sheet Daily
Software that physicians and patients could use to inform value assessments for cancer drugs could be available within a year.
You may also be interested in...
Research presented at the American Society for Clinical Oncology annual meeting evaluates cancer drug costs and benefits using two value frameworks meant to assist physicians and patients in treatment decisions.
Study's finding is somewhat surprising for Europe, given the greater national involvement in drug prices in the region; ASCO and ESMO value frameworks don't appear to drive oncology pricing decisions regardless of the reimbursement system.
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.